Abstract:It is well known that 5‐methylcytosine (m5C) is involved in variety of crucial biological processes in cancers. However, its biological roles in lung adenocarcinoma (LAUD) remain to be determined. The LUAD samples were used to assess the clinical value of NOP2/Sun RNA Methyltransferase 2 (NSUN2). Dot blot was used to determine global m5C levels. ChIP and dual‐luciferase assays were performed to investigate the MYC‐associated zinc finger protein (MAZ)‐binding sites in NSUN2 promoter. RNA‐seq was used to explore the downstream molecular mechanisms of NSUN2. Dual luciferase reporter assay, m5C‐RIP‐qPCR, and mRNA stability assay were conducted to explore the effect of NSUN2‐depletion on target genes. Cell viability, transwell, and xenograft mouse model were designed to demonstrate the characteristic of NSUN2 in promoting LUAD progression. The m5C methyltransferase NSUN2 was highly expressed and caused elevated m5C methylation in LUAD samples. Mechanistically, MAZ positively regulated the transcription of NSUN2 and was related to poor survival of LUAD patients. Silencing NSUN2 decreased the global m5C levels, suppressed proliferation, migration and invasion, and inhibited activation of PI3K‐AKT signaling in A549 and SPAC‐1 cells. Phosphoinositide‐3‐Kinase Regulatory Subunit 2 (PIK3R2) was upregulated by NSUN2‐mediated m5C methylation by enhancing its mRNA stabilization and activated the phosphorylation of the PI3K‐AKT signaling. The present study explored the underlying mechanism and biological function of NSUN2‐meditated m5C RNA methylation in LUAD. NSUN2 was discovered to facilitate the malignancy progression of LUAD through regulating m5C modifications to stabilize PIK3R2 activating the PI3K‐AKT signaling, suggesting that NSUN2 could be a novel biomarker and promising therapeutic target for LUAD patients.

Regulation and Site-Specific Covalent Labeling of <i>NSUN2</i> via Genetic Encoding Expansion

Regulation and Site-Specific Covalent Labeling of NSUN2 via Genetic Encoding Expansion

Precise Regulation and Site-specifically Covalent Labeling of NSUN2 Enable by Genetic Encoding Expansion

Determining RNA Natural Modifications and Nucleoside Analog-Labeled Sites by a Chemical/Enzyme-Induced Base Mutation Principle

N-6-Allyladenosine: A New Small Molecule for RNA Labeling Identified by Mutation Assay

Precise Identification of an RNA Methyltransferase's Substrate Modification Site

Nature-Inspired Chemical Probes for In-Cell Labeling of Lipidized RNA and Identification of New Regulatory Enzymes

Substrate Diversity of NSUN Enzymes and Links of 5-Methylcytosine to Mrna Translation and Turnover

Sequence- and Structure-Selective Mrna M5c Methylation by NSUN6 in Animals

Chemical tagging for sensitive determination of uridine modifications in RNA

Site-specific Covalent Labeling of Large RNAs with Nanoparticles Empowered by Expanded Genetic Alphabet Transcription

Phosphorothioate-Based Site-Specific Labeling of Large RNAs for Structural and Dynamic Studies

5-methylcytosine promotes mRNA export — NSUN2 as the methyltransferase and ALYREF as an m5C reader

A general strategy exploiting m5C duplex-remodelling effect for selective detection of RNA and DNA m5C methyltransferase activity in cells

NSUN2-Mediated m5C Methylation and METTL3/METTL14-Mediated m6A Methylation Cooperatively Enhance p21 Translation.

Metabolic Recoding of NSUN2-Mediated m5C Modification Promotes the Progression of Colorectal Cancer via the NSUN2/YBX1/m5C-ENO1 Positive Feedback Loop

NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma

Posttranscriptional Site-Directed Spin Labeling of Large RNAs with an Unnatural Base Pair System under Non-Denaturing Conditions

NSUN2 promotes lung adenocarcinoma progression through stabilizing PIK3R2 mRNA in an m5C‐dependent manner

CIGAR‐seq, a CRISPR/Cas‐based method for unbiased screening of novel mRNA modification regulators

NSUN2-mediated RNA methylation: Molecular mechanisms and clinical relevance in cancer